These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9736177)

  • 41. Colitis-associated sclerosing cholangitis in children: a single centre experience.
    Noble-Jamieson G; Heuschkel RB; Torrente F; Hadzic N; Zilbauer M
    J Crohns Colitis; 2013 Nov; 7(10):e414-8. PubMed ID: 23485432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ann Med; 1994 Oct; 26(5):345-9. PubMed ID: 7826595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
    Wolf JM; Rybicki LA; Lashner BA
    Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
    Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
    J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.
    De Maria N; Colantoni A; Rosenbloom E; Van Thiel DH
    Hepatogastroenterology; 1996; 43(12):1472-9. PubMed ID: 8975951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
    Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
    Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review.
    Othman MO; Dunkelberg J; Roy PK
    Arab J Gastroenterol; 2012 Sep; 13(3):103-10. PubMed ID: 23122450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Possible treatment modalities of primary sclerosing cholangitis].
    Lengyel G; Tulassay Z
    Orv Hetil; 2005 Dec; 146(49):2479-83. PubMed ID: 16398312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.
    Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF
    Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Celiac disease, inflammatory colitis, and primary sclerosing cholangitis in a girl with Turner's syndrome.
    Lacaille F; Canioni D; Bernard O; Fabre M; Brousse N; Schmitz J
    J Pediatr Gastroenterol Nutr; 1995 Nov; 21(4):463-7. PubMed ID: 8583302
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of primary sclerosing cholangitis with ursodeoxycholic acid].
    Stiehl A; Raedsch R
    Z Gastroenterol Verh; 1989 Jul; 24():136. PubMed ID: 2474928
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
    Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
    Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Bile acids in liver diseases--current indications].
    Stiehl A
    Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.
    Gohlke F; Lohse AW; Dienes HP; Löhr H; Märker-Hermann E; Gerken G; Meyer zum Büschenfelde KH
    J Hepatol; 1996 Jun; 24(6):699-705. PubMed ID: 8835745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Primary sclerosing cholangitis and systemic lupus erythematosus].
    Audan A; Bruley Des Varannes S; Georgelin T; Sagan C; Cloarec D; Serraz H; Le Bodic L
    Gastroenterol Clin Biol; 1995 Jan; 19(1):123-6. PubMed ID: 7720973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
    Rudolph G; Endele R; Senn M; Stiehl A
    Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.